Abstract:Small animal models such as mice have been extensively used to study human disease and to develop new therapeutic interventions. Despite the wealth of information gained from these studies, the unique characteristics of mouse immunity as well as the species specificity of viral diseases such as human immunodeficiency virus (HIV) infection led to the development of humanized mouse models. The earlier models involved the use of C. B 17 scid/scid mice and the transplantation of human fetal thymus and fetal liver termed thy/liv (SCID-hu) 1, 2 or the adoptive transfer of human peripheral blood leukocytes (SCID-huPBL) 3. Both models were mainly utilized for the study of HIV infection. One of the main limitations of both of these models was the lack of stable reconstitution of human immune cells in the periphery to make them a more physiologically relevant model to study HIV disease. To this end, the BLT humanized mouse model was developed. BLT stands for bone marrow/liver/thymus. In this model, 6 to 8 week old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunocompromised mice receive the thy/liv implant as in the SCID-hu mouse model only to be followed by a second human hematopoietic stem cell transplant 4. The advantage of this system is the full reconstitution of the human immune system in the periphery. This model has been used to study HIV infection and latency 5-8. We have generated a modified version of this model in which we use genetically modified human hematopoietic stem cells (hHSC) to construct the thy/liv implant followed by injection of transduced autologous hHSC 7, 9. This approach results in the generation of genetically modified lineages. More importantly, we adapted this system to examine the potential of generating functional cytotoxic T cells (CTL) expressing a melanoma specific T cell receptor. Using this model we were able to assess the functionality of our transgenic CTL utilizing live positron emission tomography (PET) imaging to determine tumor regression (9). The goal of this protocol is to describe the process of generating these transgenic mice and assessing in vivo efficacy using live PET imaging. As a note, since we use human tissues and lentiviral vectors, our facilities conform to CDC NIH guidelines for Biosafety Level 2 (BSL2) with special precautions (BSL2+). In addition, the NSG mice are severely immunocompromised thus, their housing and maintenance must conform to the highest health standards (http://jaxmice.jax.org/research/immunology/005557-housing.html).

Modeling Human Leukemia Immunotherapy in Humanized Mice

Protocol to establish a stable MLL-AF9_AML mouse model.

Modeling Anti-Cd19 CAR T Cell Therapy in Humanized Mice with Human Immunity and Autologous Leukemia.

[Establishment of Mouse Model with Humanized Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia].

Human Immune System Mice With Autologous Tumor for Modeling Cancer Immunotherapies

[Development of HPV16 Positive Cervical Cancer Model in the Hu-Pbl-scid Mouse and Its Immunological Features].

An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses

Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases.

Abstract 395: Rapid engraftment of human primary acute leukemic cells in NOD/SCID mice by intrasplenic inoculation: a robust human primary leukemia (Hukemia) model for preclinical evaluation of new therapies

[Establishment of Human Acute B-lymphoblastic Leukemia NOD/SCID/IL2 Receptor Γ Chain(null) Neonatal Mouse Xenotransplant Model].

Engineering and Characterization of Hu3A4: A Novel Humanized Antibody with Potential As a Therapeutic Agent Against Myeloid Lineage Leukemias

XactMice: Humanizing Mouse Bone Marrow Enables Microenvironment Reconstitution in a Patient-Derived Xenograft Model of Head and Neck Cancer.

Abstract 3960: Establishment of humanized mouse models engrafted with luciferase-expressing acute myeloid leukemia cell lines

Using the BLT Humanized Mouse As a Stem Cell Based Gene Therapy Tumor Model

Abstract 5345: Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide vaccines

Establishment of Mouse Model with Humanized Chronic Myeloid Leukemia

New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia

Humanized Rodent Models for Cancer Research

Humanized Mouse Models With Functional Human Lymphoid And Hematopoietic Systems Through Human Hematopoietic Stem Cell And Human Fetal Thymic Tissue Transplantation

Humanized NOD-SCID IL2rg–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies.

Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation